Baseline prostate-specific antigen testing at a young age.

Published

Journal Article (Review)

CONTEXT: Prostate cancer screening is highly controversial, including the age to begin prostate-specific antigen (PSA) testing. Several studies have evaluated the usefulness of baseline PSA measurements at a young age. OBJECTIVE: Review the literature on baseline PSA testing at a young age (≤60 yr) for the prediction of prostate cancer risk and prognosis. EVIDENCE ACQUISITION: PubMed was searched for English-language publications on baseline PSA and prostate cancer for the period ending April 2011. EVIDENCE SYNTHESIS: In most published series, median PSA levels in the general male population range from approximately 0.4 to 0.7 ng/ml in men in their 40s and from approximately 0.7 to 1.0 ng/ml in men in their 50s. Evidence from both nonscreening and screening populations has demonstrated the predictive value of a single baseline PSA measurement for prostate cancer risk assessment. Specifically, men with baseline PSA levels above the age-group-specific median have a greater risk of prostate cancer diagnosis during the next 20-25 yr. Additional studies confirmed that higher baseline PSA levels at a young age are also associated with a greater risk of aggressive disease, metastasis, and disease-specific mortality many years later. CONCLUSIONS: Baseline PSA measurements at a young age are significant predictors of later prostate cancer diagnosis and disease-specific outcomes. Thus baseline PSA testing may be used for risk stratification and to guide screening protocols.

Full Text

Duke Authors

Cited Authors

  • Loeb, S; Carter, HB; Catalona, WJ; Moul, JW; Schroder, FH

Published Date

  • January 2012

Published In

Volume / Issue

  • 61 / 1

Start / End Page

  • 1 - 7

PubMed ID

  • 21862205

Pubmed Central ID

  • 21862205

Electronic International Standard Serial Number (EISSN)

  • 1873-7560

Digital Object Identifier (DOI)

  • 10.1016/j.eururo.2011.07.067

Language

  • eng

Conference Location

  • Switzerland